Recommended positive controls: HepG2, C8D30, NIH-3T3, BCL-1, Raw264.7, C2C12.
Predicted reactivity: Mouse (100%), Rat (100%), Bovine (100%).
Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH. CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway. CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway. It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination. Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.
⚠WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: cylindromatosis (turban tumor syndrome); Deubiquitinating enzyme CYLD; FLJ20180; FLJ31664; FLJ78684; probable ubiquitin carboxyl-terminal hydrolase CYLD; retinitis pigmentosa 1 homolog; Ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; Ubiquitin thioesterase CYLD; ubiquitin thiolesterase CYLD; Ubiquitin-specific-processing protease CYLD
Gene Aliases: 2010013M14Rik; 2900009M21Rik; BRSS; C130039D01Rik; CDMT; CYLD; CYLD1; CYLDI; EAC; HSPC057; KIAA0849; LRRGT00003; MFT; MFT1; mKIAA0849; Rp1; Rp1h; SBS; TEM; USPL2